The purpose of this study was to determine the effects of interferon -(IFN -) gene transfer on the growth of PC3MM2 human prostate cancer cells in nude mice. Intralesional delivery of an adenoviral vector encoding murine IFN -( AdIFN -) , but not a vector encoding bacterial -galactosidase ( AdLacZ ) , suppressed PC3MM2 tumors in a dose -dependent manner. At the highest dose ( 2Â10 9 plaque -forming units, PFU ) , a single injection of AdIFN -( but not AdLacZ ) suppressed orthotopic PC3MM2 tumors and development of metastasis by 80%, and eradicated the tumors in 20% of mice. Immunohistochemical staining showed that AdIFN -± treated tumors contained fewer microvessels, fewer proliferating cells, and more apoptotic cells than did the control tumors. Compared with controls, tumors injected with AdIFN -expressed higher levels of IFN -and inducible nitric oxide synthase ( iNOS ) and lower levels of basic fibroblast growth factor ( bFGF ) and transforming growth factor 1 ( TGF -1). In vitro analysis indicated that expression of bFGF and TGF -1 in PC3MM2 cells could be suppressed by the nitric oxide donor sodium nitroprusside. These data suggest that intratumoral delivery of the IFN -gene with adenoviral vectors could be an effective therapy for prostate cancer and that tumor suppression by AdIFN -correlated with up -regulation of iNOS and down -regulation of angiogenesis.
A n estimated 180,400 new cases of prostate cancer will be diagnosed in 2000 in the US. 1 In the same year, 31,900 prostate cancer-related deaths were expected, making it the second most common cause of cancer death among men in the US. 1 When clinical evidence suggests that the disease is confined to the prostate, radical prostatectomy or radiation therapy is the standard treatment. Whether these local therapies have improved the overall survival rate is, however, not known. Moreover, these local therapies can have severe complications, including injury to the bladder and bowel and loss of sexual function, in addition to a surgical mortality rate of approximately 1%. 2 Androgen ablative therapy is the mainstay for more advanced cases that are not confined in the prostate. However, nearly all patients ultimately become resistant to this mode of treatment, probably because of the clonal expansion of androgen -independent cells. 3 Therefore, there is need for more effective therapy for androgen -insensitive prostate cancer as well as less morbid therapy for localized prostate cancer.
One possible therapeutic for prostate cancer is interferon-( IFN -) , a member of the type I IFN family that also includes IFN -. 4 By induction of differentiation, S-phase accumulation, and apoptosis, 5 ± 7 IFN -can directly inhibit growth of tumor cells. 5, 8 IFN -can also inhibit tumor growth and metastasis indirectly by activating the nitric oxide ( NO ) -dependent tumoricidal properties of macrophages, 9, 10 by stimulating natural killer cells, 11, 12 by suppressing angiogenic molecule expression, 13 ± 15 and by modulating T-cell ±mediated responses. 16 ± 22 Extensive clinical trials concluded that IFNs can be efficacious against some hematopoietic and vascular neoplasms. 23 ± 25 Systemic IFN therapy for most solid tumors, however, has shown only limited response, 26 ± 29 probably because of insufficient accumulation of biologically active IFN in tumors. 28, 30, 31 This hypothesis is supported by pharmacokinetics study showing that the half -life of IFNin the circulation of humans is about 5 minutes. One hour after a bolus intravenous dose of 6Â10 6 units of IFN -, serum concentrations were less than 8 U /mL and after intramuscular or subcutaneous injection, they were less than 2 U /mL. 32 These concentrations are far below those required to suppress tumor cell growth, down -regulate angiogenesis, and activate macrophages, natural killer cells, and specific T-cell responses.
Sustained IFN -exposure holds promise, nevertheless, and transduction of the IFN -gene may be an effective way to achieve sustained exposure. To directly evaluate the potential of IFN -in therapy for prostate cancer, we engineered PC3MM2 human prostate cancer cells with murine IFN -and showed that the enforced expression of mouse IFN -abrogated the tumorigenicity of PC3MM2 cells in the prostates of nude mice. 33 The IFN -gene ± transduced PC3MM2 cells suppressed the tumorigenicity of bystander nontransduced parental cells as well. 33 These findings prompted us to further study effects of intralesional delivery of the IFN -gene on established PC3MM2 tumors in nude mice. We report here that intratumoral injections of an adenoviral vector encoding the IFN -gene suppressed PC3MM2 tumors in a dosedependent manner and that suppression of the PC3MM2 tumor correlated with up -regulation of inducible nitric oxide synthase ( iNOS ) and down -regulation of tumor angiogenesis by IFN -.
MATERIALS AND METHODS

Mice
Specific pathogen -free, male athymic BALB /c nude mice were purchased from the Animal Production Area, National Cancer Institute -Frederick Cancer Research Facility ( Frederick, MD ). The mice were maintained under specific pathogen -free conditions in a facility approved by the American Association for Accreditation of Laboratory Animal Care. The care and experimental procedures were in accordance with current regulations and standards of the United States Department of Agriculture, Department of Health and Human Services, and NIH. The mice were used according to institutional guidelines when they were 8 ± 16 weeks of age.
Reagents
Eagle's minimal essential medium ( MEM ) 2 , Ca 2 + -, Mg 2 + -free Hanks' balanced salt solution (HBSS ) , and fetal bovine serum (FBS ) were purchased from M. A. Bioproducts ( Walkersville, MD ). The TRI reagents ( for RNA extraction ) were purchased from Life Technologies (Grand Island, NY ). The adenoviral vector encoding the murine IFNgene ( AdIFN -) was constructed in this laboratory as described previously. 34 A replication -defective recombinant adenovirus encoding the Escherichia coli -galactosidase gene (AdLacZ) was generously provided by Dr. W. Zhang ( Baxter Healthcare, Round Lake, IL ). Both the -galactosidase and the murine IFN -genes are driven by the human cytomegalovirus promoter. AdLacZ and AdIFN -were propagated in 293 cells and purified by two -step CsCl 2 gradient centrifugation. 35 
Cell culture and preparation
The well -defined PC3 human prostate carcinoma cell line 36, 37 was used. The highly metastatic PC3MM2 cells were maintained as a monolayer culture in MEM supplemented with 10% FBS, nonessential amino acids, sodium pyruvate, vitamin A, and glutamine. The 293 human embryonic renal cells (American Type Culture Collection, ATCC, Manassas, VA ) , which have been engineered to provide E1 gene products for adenoviral vectors, 35 were maintained in DMEM supplemented with 10% FBS.
Transduction of PC3MM2 cells in vitro
The PC3MM2 cells were plated in six -well plates at a density of 10 6 /well. For evaluation of transduction efficiency, after an overnight incubation, various amounts of AdLacZ were added and incubated for 48 hours. The transduced cells were then fixed in 0.5% glutaraldehyde and stained in PBS (pH 7.3 ) containing 1 mg / mL of 5-bromo -4-chloro -3 -indolyl --D -galactopyranoside (X -Gal, Sigma Chemicals, St. Louis, MO ), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl 2 . The X -Gal ±stained cells were identified under a microscope.
For transduction with AdIFN -, the PC3MM2 cells were incubated with various amounts of AdIFN -for up to 10 days, and the medium was replaced every 24 hours. The presence of IFN -activity in the culture supernatant was determined by the bioassay described below. The infected PC3MM2 cells were scraped into the TRIreagents, and the total cellular RNA was isolated according to the manufacturer's instructions. The expression of IFNmRNA in PC3MM2 cells was determined by Northern blot analysis.
Tumor cell inoculation
PC3MM2 cells in exponential growth phase were harvested by a 1 -minute treatment with a 0.25% trypsin ±0.02% EDTA solution. The flask was tapped to detach the cells, MEM ± 10% FBS added, and the cell suspension gently agitated to produce a single-cell suspension. The cells were washed and resuspended in HBSS. Only suspensions of single cells with viability exceeding 95% (ascertained by trypan blue exclusion ) were used. Subcutaneous inoculation. PC3MM2 cells ( 2Â10 5 cells in 100 L HBSS) were injected subcutaneously on the left lateral chest wall close to the axilla of male nude mice. Tumor growth was monitored twice a week using calipers. Orthotopic inoculation. Mice were anesthetized with Nembutal and placed in the supine position. The surgical procedure was performed as detailed in our previous study. 33 Briefly, a lower midline incision was created and the prostate exposed. A tumor cell suspension (2Â10 5 cells in 20 L of HBSS) was injected into the dorsal prostatic lobes using a 30 -gauge needle, a 1-mL disposable syringe, and a calibrated push -button ±controlled dispensing device ( Hamilton Syringe, Reno, NV ) . The abdominal wound was closed in one layer with wound lips (Autoclip, Clay Adams, Parsippany, NJ ). with calipers. Any lesion that became nonpalpable was considered eradicated. Orthotopic tumors. Seven days after tumor cell inoculation, mice were anesthetized with Nembutal, the incision reopened, and the prostate tumors exposed. PBS or adenoviral vectors [ (5±20)Â10 8 plaque -forming units ( PFU ) ] in 50 L of buffer were injected into each tumor's center with a Hamilton syringe and a 30-gauge needle over 3 minutes. The needle was removed slowly after a 30 -second delay. Prostate tumors and lymph node metastases were determined at the end of the experiments (5 ±6 weeks after tumor cell inoculation ). Primary tumors (including the entire prostate ) were weighed when the experiments were terminated; regional lymph node metastasis was assessed by microscopic examination of H&E -stained serial paraffin sections.
Immunohistochemical determination of iNOS, CD31, PCNA, and TUNEL
Immunohistochemical analyses of tumor tissues were performed as described previously. 33 Briefly, the tumor tissues were cut and placed in OCT compound and snap frozen in liquid nitrogen. Frozen sections (8 ±10 m ) were fixed in cold acetone and treated with 3% H 2 O 2 in methanol (vol /vol ) . The treated slides were incubated in blocking solution and then treated with antibodies to CD31 ( to assess tumor vascularity ) or iNOS. The sections were rinsed and incubated with peroxidase -conjugated secondary antibodies. A positive reaction was visualized by incubating the slides with stable DAB and counterstaining with Mayer's hematoxylin. For immunohistochemical staining using an antibody to proliferating cell nuclear antigen (PCNA ) , paraffin sections of the tumor samples were dewaxed and stained as described for the frozen sections. Apoptotic cells in tumor lesions were identified with the TUNEL method. 33, 38 Briefly, paraffin sections were dewaxed in xylene and rehydrated and then treated with 20 g /mL proteinase K and incubated with 3% H 2 O 2 in methanol. The slides were incubated first in terminal deoxynucleotidyl transferase buffer, then with terminal deoxynucleotidyl transferase, and finally with a streptavidin ± peroxidase conjugate and stained with 3-amino-9-ethyl carbazole.
Immunofluorescence double staining for CD31 ( endothelial cells ) and TUNEL ( apoptotic cells )
Apoptotic endothelial cells in tumor tissues were examined following a protocol described previously. 39 Briefly, frozen tissue sections ( 8± 10 m ) were fixed in cold acetone for 5 minutes, acetone/ chloroform ( 1:1 ) for 5 minutes, and acetone for 5 minutes, washed with PBS, incubated with protein -blocking solution (PBS ± 5% normal horse serum and 1% normal goat serum ) for 20 minutes at room temperature, and incubated with a rat anti -mouse CD31 antibody over 18 hours at 48C. After rinsing with PBS, the slides were incubated with Texas Red -conjugated goat anti -rat antibody for 1 hour in the dark. Samples were washed with PBS containing 0.1% Brij and then with PBS. The sections were then stained by the TUNEL method using a kit (Promega, Madison, WI ) . Briefly, sections were fixed with 4% paraformaldehyde, washed with PBS, and then incubated with 0.2% Triton X -100 for 15 minutes at room temperature. After two washes with PBS, the samples were incubated with an equilibration buffer (from the kit) for 10 minutes. The reaction buffer, the equilibration buffer containing nucleotide mix, and TdT enzyme, was added and incubated in a humid atmosphere at 378C for 1 hour in the dark. The reaction was terminated by immersing the samples in 2Â SSC for 15 minutes. Samples were washed three times to remove unincorporated fluorescein -dUTP. Immunofluorescence microscopy was performed using a Â20 objective ( Zeiss Plan -Neofluar ) on an epifluorescence microscope equipped with narrow band pass excitation filters mounted in a filter wheel (Ludl Electronic Products, Hawthorne, NY ) to individually select for green and red fluorescence. Images were captured using a cooled CCD camera ( Photometrics, Tucson, AZ ) and SmartCapture software (Digital Scientific, Cambridge, England, UK ) on a computer. Images were further processed using Adobe Photoshop software (Adobe Systems, Mountain View, CA ) . RNA isolation and Northern blot analysis. Total cellular RNA was isolated from cell cultures by using the TRI reagents, and poly ( A ) RNA was extracted using a FastTrack kit ( Invitrogen, San Diego, CA ) . For Northern blot analysis, 10 g of total RNA or 1 g of mRNA was fractionated on 1% denaturing formaldehyde/agarose gels, transferred to GeneScreen nylon membrane (Dupont, Boston, MA ), and UV cross -linked. The membranes were hybridized with [
32 P ]dCTP -labeled cDNA probes in a hybridization buffer ( Amersham ) and washed two or three times at 50 ±608C with 30 mM NaCl /3 mM sodium citrate pH 7.2/ 0.1% sodium dodecyl sulfate. The DNA probes used were cDNA fragments for human basic fibroblast growth factor (bFGF ), human transforming growth factor-1 (TGF -1) , murine iNOS, murine IFN -, and murine -actin. Bioassay for IFN -activity. IFN -activity was determined as described previously. 40 Statistical analysis. The statistical significance of the results was determined by two -tailed Student's t test.
RESULTS
Effects of transduction of PC3MM2 cells in vitro with adenoviral vectors
We first evaluated the transduction efficiency of adenoviral vectors in PC3MM2 cells. PC3MM2 cells were infected with AdLacZ at different MOI for 48 hour and stained with XGal. We found that 100% of PC3MM2 cells were stained blue at 30 MOI. Cells infected with 1± 100 MOI of AdIFN -, but not with AdLacZ, expressed increasing levels of IFNmRNA and secreted 50 ±7,000 units of IFN -activity /10 ing tumor formation. PC3MM2 cells were infected for 48 hours with 30 MOI of AdIFN -or AdLacZ. Control or infected cells were implanted into the prostate of nude mice (2Â10 5 /mouse) . Prostate tumor weight and regional lymph node metastases were examined 4 weeks later. Data in Table  1 show that mice inoculated with uninfected or AdLacZtransduced PC3MM2 cells developed fast -growing tumors in prostates and metastases in regional lymph nodes in all mice. In contrast, AdIFN -± transduced PC3MM2 cells failed to produce either local tumors or lymph node metastases.
Dose -dependent suppression of PC3MM2 tumors by AdIFN -therapy
We next determined the minimal and optimal doses of AdIFN -required to suppress or eradicate established PC3MM2 tumors in a subcutaneous model. When tumors reached 4 ±6 mm in diameter, PBS, 2Â10 9 PFU of AdLacZ, or increasing doses [ ( 0.25 ±2 )Â10 9 PFU /injection] of AdIFN -were intralesionally injected twice a week for 4 consecutive weeks. Figure 1 shows that treatment with AdIFN -led to tumor regression in a dose -dependent fashion: tumor growth was not affected by injections of 0.25Â10 9 or 0.5Â10 9 but was significantly inhibited by injections of 1Â10 9 or 2Â10 9 PFU of AdIFN -. A single injection of AdIFN -at any dose had no significant effect on the growth of PC3MM2 tumors in the subcutis ( data not shown) . Growth of tumors was slightly slowed by 2Â10 9 PFU of AdLacZ (Fig 1 ) , possibly caused by nonspecific viral toxic effects. Eradication of subcutaneous tumors occurred in 80% ( 8 of 10 ) of mice receiving 2Â10 9 PFU of AdIFN -/ injection. Because the therapeutic effects were observed only in mice treated with 1Â10 9 or 2Â10 9 PFU of AdIFN -, these two doses were used in the remaining experiments.
AdIFN -therapy on orthotopic tumors
PC3MM2 cells ( 2Â10 5 ) were implanted into the dorsal prostatic lobes. Seven days later, prostate tumors were treated by a single intralesional injection with PBS or with 1Â10 9 or 2Â10 9 PFU of AdLacZ or AdIFN -. As shown in Figure 2 , a single injection with AdLacZ at either dose did not affect growth of PC3MM2 tumors. In contrast, progression of PC3MM2 tumors was suppressed by 80% and 60% in mice treated with 2Â10 9 and 1Â10 9 of AdIFN -, respectively. In addition, the injection with 2Â10 9 PFU of AdIFNeradicated tumors in 20% of mice (2 of 10 ). Regional lymph 9 PFU of AdLacZ or AdIFN -. One week later, the tumors were collected. Paraffin sections were prepared for H&E staining, for TUNEL assay, and for immunohistochemical staining using antibody to PCNA. Snap -frozen sections were prepared for immunohistochemical staining using antibodies to CD31 and iNOS. CAO, SU, LU, ET AL: IFN-GENE THERAPY FOR PROSTATE CANCER node metastasis, identified on H&E -stained slides under a microscope, was observed in 100% of mice treated with PBS and AdLacZ. Lymph node metastasis was found in only 20% of mice treated with 1Â10 9 or 2Â10 9 PFU of AdIFN -.
Immunohistochemical analysis
PC3MM2 cells were implanted into the prostate of nude mice. One week later, the mice were intralesionally injected with PBS or 1Â10 9 PFU of either AdLacZ or AdIFN -. Tumor samples were collected 5 days later for immunohistochemical staining ( Fig 3 ) . H&E staining indicated a massive necrosis in tumors treated with AdIFN -, but not in those treated with PBS or AdLacZ. Anti -CD31 antibody staining revealed that tumors treated with PBS or AdLacZ were well vascularized, whereas those treated with AdIFN -were not ( Fig 3) . Most cells in tumors treated with PBS and AdLacZ stained intensively by a monoclonal antibody against PCNA, which is expressed mainly in the late G1 and M phase of the cell cycle. 41 In tumors treated with AdIFN -, fewer cells were PCNA positive. However, TUNEL staining showed few positive cells in tumors exposed to PBS or AdLacZ, whereas a large number of cells in the nonnecrotic portions of tumors treated with AdIFN -stained positively. iNOS was detected in tumors treated with AdIFN -but not in those treated with PBS or AdLacZ ( Fig 3 ) . Finally, the CD31 /TUNEL fluorescent double -labeling technique revealed that many endothelial cells and tumor cells ( green reaction , Fig 4 ) around them in tumors treated with AdIFN -, but not PBS and AdLacZ, underwent apoptosis (yellow reaction, Fig 4 ) . Northern blot analyses. Northern blot analysis was performed to further explore the potential mechanisms responsible for the therapeutic effects of AdIFN -. Orthotopic PC3MM2 tumors were intralesionally injected with PBS, AdLacZ, or AdIFN -(10 9 PFU /mouse) . Three or five days later, mice were killed, and tumor tissue mRNA was then extracted and analyzed by Northern blotting ( Fig 5A ) . High levels of IFN -and iNOS mRNA were found in tumors treated with AdIFN -, confirming the up-regulation of iNOS in tumors revealed by the immunohistochemistry ( Fig 3) . PC3MM2 tumors expressed high levels of bFGF and TGF -1, which were not significantly altered by treatment with AdLacZ ( Fig 5A ) . However, expression of both bFGF and TGF -1 was reduced by 20± 50% by intratumoral injection of AdIFN - ( Fig 4A ) . Because of its species -restricted activity, IFN -may not be able to directly down -regulate bFGF and TGF -1 in PC3MM2 tumors. We therefore determined whether the expression of bFGF and TGF -1 could be regulated by NO, the product of iNOS that regulates many biological processes. PC3MM2 cells were incubated for 3 days with 0, 0.3, or 1 mM sodium nitroprusside ( SNP ) , a compound that constitutively releases NO. As shown in Figure 4B , expression of both bFGF and TGF -1 was reduced by more than 60% in cells treated with 1 mM SNP.
DISCUSSION
In previous studies, we have demonstrated that enforced expression of murine IFN -in PC3MM2 cells as well as in several other lines of human and murine tumor cells abrogated their tumorigenicity and metastasis potential and that the IFN -±producing cells could suppress tumor formation by bystander parental cells. 33, 40, 42, 43 Moreover, we showed that intralesional injection of AdIFN -into UV2237m murine fibrosarcoma could both eradicate the primary tumors and confer systemic immunity to the cured animals. 34 In the present study, we further investigated the effectiveness of AdIFN -± mediated IFN -gene therapy against established PC3MM2 tumors in nude mice. Our data clearly demonstrated that PC3MM2 cells were susceptible to adenovirus infection and that intralesional injection of AdIFN -could effectively suppress primary tumors in the prostate and block the development of metastasis in the regional lymph nodes. From these data, we conclude that IFN -gene therapy could be an effective modality in treating prostate cancer.
It has been reported that ex vivo transduction of human IFN -gene by a replication-defective adenovirus in as few as 1% of implanted cells blocked tumor formation and that direct delivery of human IFN -gene into established tumors using the adenoviral vector generated high local concentrations of IFN -, inhibited tumor growth, and in many cases caused complete tumor regression. 44 Suppression of tumor progression by the therapy in that study was due to direct effects of IFN -on tumor cells. 44 Because the action of IFN -is species -restricted, the therapeutic effects of AdIFN -on PC3MM2 tumors in the present study must have resulted indirectly from modulation of tumor environ- ment, which includes IFN -±mediated activation of host defense systems and suppression of tumor angiogenesis. 33, 34, 40, 42, 43 This conclusion was supported by the results of immunohistochemical and Northern blot analyses showing that intralesional injection of AdIFN -, but not PBS or AdLacZ, led to a significant reduction in microvessel density and an up-regulation of iNOS expression in the orthotopic PC3MM2 tumors.
In addition to confirming our previous findings that the suppression of tumor growth and metastasis by IFN -is associated with inhibition of tumor angiogenesis 33, 40 and induction of iNOS, 42, 43 data presented in this study further suggested that suppression of tumor angiogenesis was caused by NO -dependent mechanisms. We base this conclusion on the following findings: First, AdIFNinduced the expression of iNOS and suppressed the expression of the angiogenic molecule bFGF in PC3MM2 tumors. Second, the expression of bFGF in PC3MM2 cells was reduced in vitro by treatment of the cells with the NO donor SNP. Third, NO also directly inhibits proliferation of endothelial cells. 45 Immunofluorescent double staining further suggested that the reduction of microvessel density in tumors injected with AdIFN -was due to an increased apoptosis of endothelial cells. This apoptosis of endothelial cells could be caused by the direct toxic effects of NO, 46 which can be generated in either the endothelial cells 47, 48 or tumor-infiltrating macrophages. 33, 49 Alternatively, our data suggested that the apoptosis could also be due indirectly to the down -regulation of angiogenic molecules by NO.
TGF -, markedly elevated in prostate cancer tissues, plays an important role in both the malignant transformation of prostate epithelial cells and metastasis of prostate cancer. 50, 51 Malignant transformation of prostate epithelial cells is associated with a reduction of TGF -receptor expression and an overexpression of TGF -. 50 ± 53 The overproduction of TGF -by prostate cancer cells can promote extracellular matrix formation, induce angiogenesis, and inhibit host immune function. 50 By modulating matrix -degrading protease expression and activity, 54, 55 TGF -may also promote metastasis in prostate cancers. Therefore, the suppression of tumor progression by AdIFNmay be partially attributable to NO -mediated downregulation of TGF -1. Interestingly, similar observations were made in another tumor system, in which induction of tumor regression by bacterial products was associated with a decrease in TGF -1 and an increase in NO in tumors. 56, 57 It is noteworthy that orthotopic PC3MM2 tumors were more susceptible to AdIFN -therapy than were their subcutaneous counterparts. Although it is not clear what caused this differential susceptibility, this observation cautions that experimental therapeutic studies for prostate cancer should be performed in the orthotopic organ.
